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rohn's disease is a chronic inflammatory disorder of unknown origin involving various sites in the gastrointestinal tract. Several environmental, microbial, immunologic, genetic, and life-style factors have been suggested to play a role in the initiation of the disease. 1, 2 Heterogeneity is observed in terms of disease location, behavior, age of onset, and surgical history. There is some support for the concept that this heterogeneity may be in large measure genetically determined. [3] [4] [5] [6] Genome-wide scans performed in patients with inflammatory bowel disease (IBD) have failed to find a major unique susceptibility locus and have prompted the general agreement that Crohn's disease is a polygenic entity in which several genes may contribute to susceptibility. The major IBD susceptibility loci identified, demonstrating significant or suggestive evidence for linkage, have been on chromosomes 16 (IBD1), 12 (IBD2), 6 (IBD3, the human leukocyte antigen [HLA] region), 14 (IBD4), 5 (IBD5), 19 (IBD6), 1, 7, and 3. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] Several groups have recently reported associations between the NOD2/CARD15 gene, which is located in human chromosome 16q (IBD1), and susceptibility to Crohn's disease. [17] [18] [19] A frameshift mutation (Leu1007fsinsC) and two nonsynonymous single-nucleotide polymorphisms (SNPs Arg702Trp and Gly908Arg), which were found in 30% of the patients, were significantly associated with the disease overall. Several studies also have reported an association between NOD2/CARD15 and ileal/fibrostenosing disease. [20] [21] [22] [23] [24] The HLA region (IBD3) on chromosome 6 contains more than 200 genes, many of which participate in the regulation of immune and inflammatory responses, therefore providing ideal candidates for etiologic investigations. IBD3 on chromosome 6 has been involved mainly in susceptibility to ulcerative colitis, [25] [26] [27] whereas the results in Crohn's disease in white patients have been contradictory, and some important studies have not found any overall association. 25 In other instances, positive associations with HLA-DRB1*01, 28, 29 which were later attributed to the DRB1*0103 subtype, 20, 30 DRB1*1302 [31] [32] [33] , and DRB1*07, 20, 29, 32, 34 and negative associations with HLA-DR2, 20, 32, 35 which were attributed to the DRB1*1501 subtype, 20, 35 and with HLA-DRB1*03 29, 32, 34 have been reported. The results of previous studies of the HLA class II genes produced conflicting data, probably due to methodological and ethnic differences, as well as disease heterogeneity. Besides, the linkage disequilibrium seen across the HLA region results in highly conserved haplotypes, making the interpretation of results difficult. Other genes or markers (ie, tumor necrosis factor, major histocompatibility complex class I chain-like gene A, and HSP-70) in addition to HLA-DR have also been reported to be associated with Crohn's disease. [36] [37] [38] As HLA genes appear to confer only a modest risk of Crohn's disease overall, we speculated that associations might be stronger or present only in specific patient subgroups. To examine this hypothesis, the patient population was stratified by phenotype, as defined by the Vienna classification, 39 and on the basis of the presence or absence of the NOD2/CARD15 mutations to look for susceptibility genes being present in only one or some of these subpopulations. The study was performed in two steps. First, we performed a study of HLA class II DRB1 genes in Crohn's disease patients overall. Second, we stratified the patients into those patients who were positive or negative for any of the three NOD2/CARD15 gene polymorphisms.
MATERIALS AND METHODS

Patients and Control Subjects
The study group consisted of 210 adult, unrelated, white Spanish patients (53% women; median follow-up 9.9 years; follow-up range 1-44 years) who had been recruited from a single center. The diagnosis of Crohn's disease was based on standard clinical, radiologic, endoscopic, and histologic data following the criteria of Lennard-Jones. 40 Patients and data are regularly followed up in the Inflammatory Bowel Disease Unit at San Carlos University Hospital, Madrid. Phenotypic details were obtained from clinical histories and personal interviews of patients. Disease phenotype was determined following the Vienna classification. 39 Locations were designated as follows: L1 (terminal ileum); L2 (colonic); L3 (ileocolonic); and L4 (upper gastrointestinal). Behavior was designated as follows: B1 (inflammatory, nonstricturing, nonpenetrating); B2 (stricturing); and B3 (penetrating). Perianal disease was defined by the presence of perianal abscesses, fistulas, and/or ulcers. A group of 343 healthy, white, unrelated subjects (61% women) from the Madrid region (mainly hospital employees and blood donors) were selected as control subjects.
DNA Isolation and HLA Class II Genotyping
DNA was extracted from fresh peripheral blood leukocytes by a "salting out" procedure with 6 mol/L NaCl after overnight incubation with proteinase K. 41 The hypervariable second exon of the HLA-DRB1 locus was amplified by a polymerase chain reaction (PCR) procedure using the appropriate primers from the 11th International Histocompatibility Workshop. 42 The quality of PCR product was assessed by agarose gel electrophoresis. From the PCR products, 5 µL (about 20 ng) was slot-blotted onto nylon membranes and cross-linked by exposure to ultraviolet light. Hybridization was performed with digoxygenin-labeled, allele-specific oligonucleotide probes from the 11th Histocompatibility Workshop to characterize the DRB1 allele groups. The results of this sequencespecific oligonucleotide PCR technique were visualized by exposing the membranes to radiographic films for 5 to 15 minutes. HLA-DR1, HLA-DR2-, HLA-DR4-, HLA-DR11-, and HLA-DR6-positive DNAs, identified in the HLA-DRB1 generic PCR and hybridization, were then specifically typed for the individual alleles within the HLA-DR1, HLA-DR2, HLA-DR4, HLA-DR11, or HLA-DR6 groups by amplification in the HLA-DRB1 group-specific PCR and by hybridization with a panel of sequence-specific oligonucleotide probes from the 11th International Histocompatibility Workshop.
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NOD2/CARD15 Polymorphisms SNP13 (Leu1007fsinsC) was genotyped using a TaqMan assay (Applied Biosystems, Foster City, CA). The primers and probes used have been described previously, 19 and the PCR products were analyzed in an ABI 7700 Sequence Detector (Applied Biosystems). SNP8 (Arg702Trp) (sense, 5Ј-CAT CTG AGA AGG CCC TGC TC(C/T)-3Ј; antisense, 5Ј-CAG ACA CCA GCG GGC ACA-3Ј) and SNP12 (Gly908Arg) (sense, 5Ј-TTG GCC TTT TCA GAT TCT GG (G/C)-3Ј; antisense, 5Ј-CCC CTC GTC ACC CAC TCT G-3Ј) were typed by allele-specific PCR. The detection of a wild-type/mutant was assessed in an ABI 7700 Sequence Detector by a SyberGreen assay. Previously sequenced samples were used as controls. In cases of doubt, samples were sequenced to confirm the result.
Statistical Analysis
The allele carriage rates in patients and control subjects were compared by the 2 test or Fisher exact test when an expected value was <5, and P values were considered to be significant at a level of <0.05. For HLA-DRB1 genotyping, the Bonferroni correction was applied. For those DRB1 alleles the results of which have already been reported, no correction has been applied. Odds ratios (ORs), 95% confidence intervals (CIs), and P values were calculated using a standard informatic package (Epi Info, version 6.02; CDC, Atlanta, GA).
RESULTS
General Analysis
Disease Susceptibility
We examined HLA-DR class II alleles. A negative association of alleles HLA-DR2 (15.7%; healthy control subjects 26.0%; P = 0.004; OR 0.53) and the DR2 subtype DRB1*1501 (11.4%; healthy control subjects 18.6%; P = 0.02; OR 0.56; 95% CI 0.33-0.96) was observed in Crohn's disease patients. Allele DRB1*07 showed a positive association with Crohn's disease (35.2%; healthy control subjects 26.8%; P = 0.03; OR 1.48; 95% CI 1.01-2.19), as did allele DRB1*0103 (6.6%; healthy control subjects 2.0%; P = 0.005; OR 3.43; 95% CI 1.27-9.55) ( Table 1) .
Disease Location
Location is a stable determinant of phenotype in Crohn's disease. Patients were classified according to the location of the lesions in four groups: terminal ileum (L1), 46.2% of patients; colonic (L2), 17.1% of patients; ileocolonic (L3), 32.8% of patients; and upper GI tract (L4), 3.8% of patients ( Table 2) . As all L4 patients also had lesions in the terminal ileum, in the statistical analysis they were considered to be part of the same group (designated Li from this point; Li = L1 + L4).
HLA DRB1*1501 showed no significant differences between groups. HLA DRB1*0701 was positively associated with the presence of ileal disease, irrespective of the presence of colonic disease, when compared with healthy control subjects (Li 38.1% [P = 0.03; OR 1.68]; L3 39.1% [P = 0.04; OR 1.75]; versus control subjects 26.8%; Li + L3 38.5%; control subjects 26.8%; P = 0.007; OR 1.71; 95% CI 1.14-2.56). The difference was even greater between ileal and colonic patients (Li + L3 38.5%; L2 19.4%; P = 0.03; OR 2.6; 95% CI 1.01-6.92) ( Table 1) .
HLA-DRB1*0103 was significantly associated with the presence of colonic disease (L2) when compared with control subjects (27.7% versus 2.0%, respectively; P < 10 −6 ; OR 18.46; 95% CI 5.86-59.52). HLA-DRB1*0103 was also more frequent in patients with ileocolonic disease (L3) than in healthy control subjects or in those with ileal (Li) disease (L3 4.3%; control subjects 2.0%; Li 0.95%), but the differences were not statistically significant. The biggest difference in DRB1*0103 frequency was found between patients with colonic (L2) and ileal (Li) disease (27.7% versus 0.95%, respectively; P < 10 −6 ; OR 40; 95% CI 4.87-873.04) ( Table 1 ). DRB1*0103 was also found to be associated with perianal disease when compared with healthy control subjects (15.5% versus 2.0%, respectively; P = 0.000005; OR 8.84; 95% CI 2.61-30.00) and compared with no perianal disease (15.5% versus 4.2%, respectively; P = 0.007; OR 4.16; 95% CI 1.22-14.22) ( Table 1) .
As perianal lesions were frequently present in patients with colonic disease (30.6%), we performed a stratified analysis to determine whether allele DRB1*0103 was primarily associated with colonic and/or perianal disease. Allele DRB1*0103 was significantly increased in colonic patients (both L2 and L2 
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Crohn's Disease in the Spanish Population + L3 patients) with no perianal lesions (L2 20%; control subjects 2.0%; P = 0.0005; OR 12; 95% CI 2.98-47.51; L2 + L3 9.1%; control subjects 2.0%; P = 0.01; OR 4.8 95% CI 1.37-16.60), but not in Li patients with perianal lesions (Li 0%; healthy control subjects 2.0%; difference was not significant) ( Table 3) .
Clinical Behavior
Each patient was also defined by clinical behavior: B1 was present in 42.4% of patients; B2 was present in 16.6% or patients; and B3 was present in 40.9% of patients ( Table 2) .
The frequency of allele DRB1*1501 was decreased in patients with inflammatory lesions when compared with control subjects (7.9% versus 18.6%, respectively; P = 0.01; OR 0.37), but no statistically significant differences were found between the different clinical behaviors.
The frequency of allele DRB1*0701 was increased in the three groups but only reached statistical significance in patients with inflammatory lesions when compared with control subjects (39.3% versus 26.8%, respectively; P = 0.02; OR 1.77).
Penetrating disease was associated with allele DRB1*0103 when compared with control subjects (9.3% versus 2.0%, respectively; P = 0.001; OR 4.92; 95% CI 1.57-15.63), although the difference was not statistically significant when compared with the other groups ( Table 1) .
As penetrating disease was common among colonic patients, we performed a stratified analysis to determine whether DRB1*0103 was primarily associated with penetrating disease or was secondary to the presence of colonic disease. The frequency of allele DRB1*0103 was significantly increased in colonic patients (both L2 and L2 + L3 patients) with no penetrating lesions (L2 patients 18.2%; control subjects 2.0% [P = 0.00001; OR 10.67; 95% CI 2.36-46.17]; L2 + L3 patients 9.8%; healthy control subjects 2.0% [P = 0.002; OR 5.22; 95% CI 1.37-19.33]) but not in ileal patients with penetrating lesions (L1 0%; healthy control subjects 2.0%; difference not significant) ( Table 3) .
Alleles DRB1*1302 and DRB1*03 were not associated with Crohn's disease overall or with any specific location or behavior.
Stratification by NOD2/CARD15 Gene Mutations
Of the 210 patients with Crohn's disease who were studied, 66 patients (31.4%) carried at least one of the three NOD2/CARD15 mutations (SNP8 14.7%; SNP12 7.6%; SNP13 12.8%), and 144 patients possessed no variant (Table  2) . A total of 9.3% of the healthy control subjects carried one of the three NOD2/CARD15 mutations (SNP8 5.4%; SNP12 2.3%; SNP13 1.6%). Ileal disease (Li) was present more frequently in NOD2/CARD15-positive patients than in NOD2/CARD15-negative patients (66.6% versus 42.3%, respectively; P = 0.001; OR 2.72; 95% CI 1.42-5.25), whereas colonic disease (L2) was present less frequently (6% versus Table 4) .
Disease Susceptibility
When we examined the association of DRB1 HLA class II alleles with NOD2/CARD15 mutation-positive and mutation-negative patients separately, no new positive or negative association was found. The negative association of DRB1*1501 was observed in NOD2/CARD15-negative patients when compared with healthy control subjects (9.7% versus 18.6%, respectively; P = 0.01; OR 0.47), but not in NOD2/CARD15-positive patients (15.1% versus 18.6%, respectively). No statistically significant difference in DRB1*1501 frequency was found between NOD2/CARD15-positive and NOD2/CARD15-negative patients.
Allele DRB1*0701 presented a higher frequency both in NOD2/CARD15 mutation-negative (34%) and NOD2/CARD15 mutation-positive patients (37.8%) when compared with control subjects (26.8%), although the differences did not reach Only the most relevant DRB1 alleles for Crohn's disease are shown. Values are given as the number of patients. See Table 2 for abbreviations not used in the text. 
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Crohn's Disease in the Spanish Population statistical significance. The presence of both NOD2/CARD15 mutation and DRB1*07 in one individual did not increase the risk for disease compared with the presence of the NOD2/CARD15 mutation alone (NOD2/CARD15-positive-DRB1*07-positive: OR 4.32; 95% CI 1.48-13.51; NOD2/CARD15-positive-DRB1*07-negative: OR 8.85; 95% CI 2.87-30.44). Allele DRB1*0103 was associated with the disease in NOD2/CARD15 mutation-negative patients compared to control subjects (9% versus 2%, respectively; P = 0.0004; OR 4.76; 95% CI 1.73-13.52), but not in NOD2/CARD15 mutation-positive patients (1.5%). There was also a significant difference between NOD2/CARD15 mutation-negative and NOD2/CARD15 mutation-positive patients (9% versus 1.5%, respectively; P = 0.04; OR 6.45) ( Table 4) .
Disease Location
The negative association with DRB1*1501 showed no differences between groups. HLA DRB1*0701 was positively associated with the presence of ileal disease, with or without colonic disease, in both NOD2/CARD15-negative and NOD2/CARD15-positive patients (37.7% and 38.5%, respectively; control subjects 26.8%). No additive effect was found between these two genomic regions for ileal lesions, as these were found with the same increased frequency in NOD2/CARD15-positive-DRB1*07-positive patients (68%) and NOD2/CARD15-positive-DRB1*07-negative patients (66%). The risk for ileal lesions was not so marked in NOD2/CARD15-negative-DRB1*07-positive patients compared to all NOD2/CARD15-positive patients (47% versus 67%, respectively; P = 0.03; OR 0.44).
The presence of HLA DRB1*0103 was increased in NOD2/CARD15-negative patients with colonic disease compared with control subjects (31.3% versus 2%, respectively; P < 10 −6 ; OR 21.82; 95% CI 6.81-71.60) and when compared with those patients with ileal disease (L2 31.3%; L1 + L3 2.7%; P = 10 −6
; OR 16.52; 95% CI 3.74-83.30) ( Table 4) . Associations between DRB1*0103 and colonic disease in the NOD2/CARD15-positive group were difficult to ascertain, due to the very small number of patients with this location of the lesions. However, the only DRB1*0103-positive patient in the NOD2/CARD15-positive group had an ileal stricturing disease and no colonic lesions.
The frequency of DRB1*0103 was also significantly higher in NOD2/CARD15-negative patients with perianal disease when compared with healthy control subjects or with patients without perianal disease (21.2% versus 5.4%, respectively; P = 0.005; OR 4.71; 95% CI 1.28-17.61). As previously shown for the totality of patients, the association of DRB1*0103 with perianal disease was secondary to colonic lesions also in the NOD2/CARD15-negative group (data not shown).
Clinical Behavior
Distribution of HLA DRB1*1501 or DRB1*0701 showed no significant differences in any of the three clinical behaviors between NOD2/CARD15-positive and NOD2/CARD15-negative patients. DRB1*0103 was associated with penetrating disease in NOD2/CARD15-negative patients when compared with healthy control subjects (13.8% versus 2%, respectively; P = 10 −6 ; OR 7.68), but differences were not significant when compared with the other subgroups. Again, the association of penetrating disease with DRB1*0103 was secondary to that with colonic lesions in the NOD2/CARD15-negative group (data not shown).
DISCUSSION
Our results have not detected any new association between HLA genes and Crohn's disease, but they showed that a strong relation exists between disease location and genetic heterogeneity.
They confirmed the association between NOD2/CARD15 mutations and ileal disease, [20] [21] [22] [23] [24] and the strong association between DRB1*0103 allele and colonic disease.
Of the associations highlighted on a recent meta-analysis, 32 our results were consistent with the positive association with HLA-DRB1*07 and the negative association with DR2 (DRB1*1501), but they did not show a decreased frequency of the allele DRB1*03 or an increased frequency of DRB1*1302.
When stratified analyses were performed, the only significant difference with the DRB1*1501 allele was that its protective role was only observed in the NOD2/CARD15-negative group.
Similar to the results of Ahmad et al, 20 the most significant differences for DRB1*07 and DRB1*0103 were seen when patients were stratified on the basis of disease location. HLA-DRB1*07 was associated with patients with ileal (L1) and ileocolonic (L3) diseases, whereas DRB1*0103 was much more frequent in patients with colonic disease (L2). When stratified by clinical behavior, the former allele was not associated with any subgroup, and the latter was associated with penetrating lesions, but this was seen to be secondary to the association between this behavior and the disease location (colonic).
Silverberg et al 43 have recently described an association between DRB1*0103 and colonic location, and our data show that this occurs in NOD2/CARD15-negative individuals, although this should be confirmed in a larger group of patients.
We studied the possible interactions between susceptibility loci located within chromosome 16 (IBD1) and within chromosome 6 (IBD3). No additive effect was found between these two regions for susceptibility to Crohn's disease nor for the presence of ileal lesions, as these were found with the same increased frequency in NOD2/CARD15-positive-DRB1*07-positive patients and in NOD2/CARD15-positive-DRB1*07-negative patients. Although both NOD2/CARD15 mutations and DRB1*0103 were associated with Crohn's disease, no additive effect was observed. This stressed the genetic heterogeneity of the disease as the former polymorphism conferred susceptibility to ileal lesions and the latter to colonic lesions. Moreover, even if the frequency of each of those two markers (NOD2/CARD15 and DRB1*0103) was increased in patients, the presence of NOD2/CARD15-positive-DRB1*0103-positive individuals was not (1/210 patients or 0.48%). Furthermore, the only NOD2/CARD15-positive-DRB1*0103-positive patient had an ileal stricturing disease without colonic lesions.
Therefore, we can conclude that there is an association between several HLA-DRB1 alleles in the IBD3 region and susceptibility to Crohn's disease:
• HLA-DRB1*1501 is a protective allele for the disease overall.
• HLA-DRB1*07 confers susceptibility to the ileal form of the disease, with (L3) or without colonic lesions (Li).
• HLA-DRB1*0103 confers susceptibility to the colonic form of the disease (L2). NOD2/CARD15 mutations confer susceptibility to the ileal form of the disease, and in their presence HLA-DRB1*1501 was not seen to be protective, HLA-DRB1*07 was not seen to confer an additive effect, and HLA-DRB1*0103 was not seen to confer additive susceptibility to the colonic form of the disease.
Clinical behavior in patients with ileal disease is partly dependent on the genetics: NOD2/CARD15-positive ileal patients have stricturing lesions more frequently, whereas NOD2/CARD15-negative-DRB1*07-positive patients with ileal disease have inflammatory (ie, nonstricturing, nonpenetrating) lesions more frequently. Also, the association between DRB1*0103 and the penetrating behavior appears to be secondary to the presence of colonic and perianal lesions found in patients carrying this allele. It is interesting to note that DRB1*0103 is strongly associated both with ulcerative colitis [25] [26] [27] and Crohn's disease located exclusively in the colon, and that these two inflammatory colonic diseases therefore appear to be genetically related. This location of Crohn's disease (L2) was seen to have a quite different genetic basis than those of the other locations (ie, NOD2/CARD15-negative, DRB1*0103-positive, and DRB1*07-negative patients) and usually has a distinct clinical behavior.
Having been established the genetic heterogeneity of IBD and its importance in the location of the disease, and secondarily its clinical form, it would be interesting to study whether other phenotypic manifestations (eg, treatment response) also show such complex genetic profiles.
